Summary

Pharmaceutical Intermediate CDMO Market Research Report by Type of Intermediate [Active Pharmaceutical Ingredients (APIs), Excipients and Additives, Biologics Intermediates, Nucleotide Intermediates], by Drug Type (Generic Drugs, Branded Drugs), by Application (Oncology, Cardiovascular Diseases, CNS & Neurological Disorders, Infectious Diseases), and by Region (North America, Europe, South America, Middle East and Africa, and Asia Pacific) Forecast till 2035

Market Overview
From 2024 to 2035, the global pharmaceutical intermediate CDMO market is projected to increase at a compound annual growth rate (CAGR) of 7.4% to reach USD 346,744.3 million. In 2024, the market was valued at USD 161,798.9 million.
The global Pharmaceutical Intermediate CDMO (Contract Development and Manufacturing Organization) market is witnessing strong growth driven by several factors. Pharmaceutical companies are increasingly outsourcing intermediate manufacturing to CDMOs to streamline operations and cut costs. The rising demand for generic drugs and biosimilars, particularly in developing regions, is significantly boosting market expansion. Additionally, rapid technological advancements in intermediate synthesis and the increasing complexity of drug molecules are encouraging companies to rely on specialized CDMO services. Emerging markets are also playing a vital role in global growth due to favorable government policies and rising healthcare infrastructure.
The market faces restraints such as stringent regulatory frameworks and complex approval processes, which can delay product timelines. High operational and capital costs, IP protection concerns, and raw material shortages also pose challenges. Moreover, there’s a lack of skilled expertise in niche chemistries. Nonetheless, opportunities lie in forming strategic collaborations with biotech firms and capitalizing on the rising trend of personalized medicine.

Market Segmentations
Global Pharmaceutical intermediate CDMO market has been segmented by type of intermediate, includes active pharmaceutical ingredients (APIS), excipients and additives, biologics intermediates, nucleotide intermediates.
In terms of drug type, the global market is divided into generic drugs, branded drug.
Based on the application types, global pharmaceutical intermediate CDMO market comprises oncology, cardiovascular diseases, CNS and neurological disorders, and infectious disease.
The market is categorized into region, includes North America, Europe, South America, Middle East and Africa, and Asia Pacific.

Regional Insights
North America leads the global pharmaceutical intermediate CDMO market, with the U.S. at the forefront due to its advanced technology, substantial R&D funding, and strict FDA regulations. Canada’s growing biopharma industry also adds to the region’s strength.
In Europe, the market caters to both local and international pharmaceutical firms, focusing on innovation, compliance, and high-quality solutions for complex chemical syntheses. The adoption of eco-friendly practices and support for circular economy initiatives are transforming manufacturing approaches.
Asia Pacific stands out as the fastest-growing region, mainly fueled by China and India's affordable production capacity and expanding biopharma sectors. The region offers large-scale manufacturing capabilities with integrated facilities and cost efficiency.
Latin American CDMOs face challenges due to inconsistent regulations, though regional collaborations are pushing for harmonization. The region benefits from geographical proximity to North America and a cost-effective labor force, although infrastructural shortcomings have limited rapid expansion.
In the Middle East and Africa, CDMOs are primarily engaged in producing intermediates for generics and essential medications, mostly targeting local markets and nearby regions. Its strategic location between Europe and Asia enhances its relevance in global supply chains, giving the region potential to grow into a critical link in pharmaceutical logistics and production networks.

Major Players
Raghava Life Sciences Pvt LTD., Actylis, Chiracon GmbH, Codexis, Inc., Arkema S.A., Lonza Group AG, Thermo Fisher Scientific, Cambrex Corporation, Catalent, Inc., Zhejiang Jiuzhou Pharmaceutical Co Ltd are the major competitors of the global pharmaceutical intermediate CDMO market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ................................................... 18
1.1 MARKET OVERVIEW: ................... 19
1.2 MARKET SEGMENTATION ......... 19
1.3 COMPETITIVE LANDSCAPE ........ 19
1.4 FUTURE OUTLOOK ......................... 20
2 MARKET INTRODUCTION ............................................... 22
2.1 DEFINITION ...................................... 22
2.2 SCOPE OF THE STUDY .................. 22
2.3 RESEARCH OBJECTIVE ................ 22
2.4 MARKET STRUCTURE .................. 23
3 RESEARCH METHODOLOGY .......................................... 24
3.1 OVERVIEW ........................................ 24
3.2 DATA FLOW ...................................... 26
3.2.1 Data Mining Process ........... 26
3.3 PURCHASED DATABASE: ............. 27
3.4 SECONDARY SOURCES: ................ 28
3.4.1 Secondary Research Data Flow: ......................................................... 29
3.5 PRIMARY RESEARCH: ................... 30
3.5.1 Primary Research DATA FLOW: ......................................................... 31
3.5.2 Primary Research: Number of Interviews conducted ........................... 32
3.5.3 Primary Research: Regional Coverage ................................................ 32
3.6 APPROACHES FOR MARKET END USER ESTIMATION: ................. 33
3.6.1 Revenue Analysis Approach .............................................................. 33
3.6.2 Data forecasting ................. 34
3.6.3 Data Forecasting Technique .............................................................. 34
3.7 DATA MODELING ............................ 35
3.7.1 microeconomic factor analysis: ......................................................... 35
3.7.2 Data modeling: ................... 36
3.8 TEAMS AND ANALYST CONTRIBUTION ............................................. 37
4 MARKET DYNAMICS ........................................................ 39
4.1 INTRODUCTION ............................... 39
4.2 DRIVERS ............................................. 40
4.2.1 Increasing Outsourcing by Pharmaceutical Companies ....................... 40
4.2.2 Rising Demand for Generic Drugs and Biosimilars .............................. 40
4.2.3 Technological Advancements in Intermediate Synthesis ..................... 40
4.2.4 Growing Complexity of Drug Molecules .............................................. 40
4.2.5 Expansion in Emerging Markets ......................................................... 40
4.3 RESTRAINTS .................................... 42
4.3.1 Stringent Regulatory Compliance and Complex Approval Processes .... 42
4.3.2 High Operational and Capital Expenditure Costs ................................. 42
4.3.3 Property (IP) Risks and Confidentiality Concerns ................................ 42
4.3.4 Supply Chain Disruptions and Raw Material Shortages ........................ 42
4.3.5 Limited Expertise in Advanced Technologies and Niche Chemistry ...... 42
4.4 OPPORTUNITY ................................. 44
4.4.1 Strategic Partnerships with Biotech Firms .......................................... 44
4.4.2 Focus on Personalized Medicine Solutions ........................................ 44
4.5 IMPACT ANALYSIS OF COVID – 19 ......................................................... 45
5 MARKET FACTOR ANALYSIS .......................................... 46
5.1 SUPPLY CHAIN ANALYSIS ......... 46
5.1.1 Raw Material Sourcing & Procurement ............................................... 46
5.1.2 Research, Development, & Process Optimization ................................ 46
5.1.3 Manufacturing & Quality Control ........................................................ 47
5.1.4 Packaging, Storage, & Logistics & Distribution & Customer Delivery .... 47
5.2 PORTER’S FIVE FORCES MODEL ............................................................. 48
5.2.1 Threat of New Entrants (Low to Moderate) ......................................... 48
5.2.2 Bargaining Power of Suppliers (Moderate) ......................................... 48
5.2.3 Threat of Substitutes (Low to Moderate) ............................................ 49
5.2.4 Bargaining Power of Buyers (High) .................................................... 49
5.2.5 Intensity of Rivalry (High) .... 49
6 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE .... 51
6.1 INTRODUCTION ............................... 51
6.2 ACTIVE PHARMACEUTICAL INGREDIENTS (APIS) .......................... 52
6.3 EXCIPIENTS & ADDITIVES .......... 52
7 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE .................... 53
7.1 INTRODUCTION ............................... 53
7.2 GENERIC DRUGS .............................. 54
7.3 BRANDED DRUGS ............................ 54
8 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION ................. 55
8.1 INTRODUCTION ............................... 55
8.2 ONCOLOGY ........................................ 56
8.3 CARDIOVASCULAR DISEASES ... 56
8.4 CNS & NEUROLOGICAL DISORDERS ........................................................ 56
8.5 INFECTIOUS DISEASES ................. 57
8.6 OTHERS .............................................. 57
9 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION ........................... 58
9.1 GLOBAL .............................................. 58
9.2 NORTH AMERICA ........................... 59
9.2.1 USA ................................... 63
9.2.2 CANADA ............................ 64
9.3 EUROPE .............................................. 65
9.3.1 united kingdom................... 69
9.3.2 germany ............................. 71
9.3.3 france ................................ 72
9.3.4 italy ................................... 73
9.3.5 spain ................................. 74
9.3.6 RUSSIA .............................. 75
9.3.7 rest of europe ..................... 76
9.4 ASIA PACIFIC ................................... 77
9.4.1 china.................................. 82
9.4.2 South Korea ....................... 83
9.4.3 indiA .................................. 84
9.4.4 Japan ................................ 85
9.4.5 indonesia ........................... 86
9.4.6 malaysia ............................ 87
9.4.7 thailand .............................. 88
9.4.8 rest of asia pacific .............. 89
9.5 SOUTH AMERICA ........................... 90
9.5.1 Mexico ............................... 95
9.5.2 Brazil ................................. 96
9.5.3 argentina............................ 97
9.5.4 rest of south america .......... 98
9.6 MIDDEL EAST AND AFRICA ........ 99
9.6.1 gcc countries ..................... 105
9.6.2 south africa ........................ 106
9.6.3 rest of middle east & africa ............................................................... 107
10 COMPETITIVE LANDSCAPE ............................................ 108
10.1 INTRODUCTION ............................... 108
10.2 MARKET SHARE ANALYSIS, 2024SS .................................................... 109
10.3 COMPETITOR DASHBOARD......... 110
11 COMPANY PROFILES ...................................................... 111
11.1 RAGHAVA LIFE SCIENCES PVT LTD ...................................................... 111
11.1.1 COMPANY OVERVIEW ......... 111
11.1.2 Key Development ................ 112
11.1.3 SWOT ANALYSIS ................ 112
11.1.4 Key Strategy ....................... 113
11.2 ACTYLIS ............................................. 114
11.2.1 COMPANY OVERVIEW ......... 114
11.2.2 PRODUCT OFFERED ............ 115
11.2.3 Key Development ................ 115
11.2.4 SWOT ANALYSIS ................ 116
11.2.5 Key Strategy ....................... 116
11.3 CHIRACON GMBH ........................... 117
11.3.1 COMPANY OVERVIEW ......... 117
11.3.2 PRODUCT OFFERED ............ 118
11.3.3 SWOT ANALYSIS ................ 118
11.3.4 Key Strategy ....................... 119
11.4 CODEXIS, INC. ................................... 120
11.4.1 COMPANY OVERVIEW ......... 120
11.4.2 PRODUCT OFFERED ............ 121
11.4.3 Key Development ................ 121
11.4.4 SWOT ANALYSIS ................ 122
11.4.5 financial analysis ................ 123
11.4.6 Key Strategy ....................... 123
11.5 ARKEMA S.A. ................................... 124
11.5.1 COMPANY OVERVIEW ......... 124
11.5.2 PRODUCT OFFERED ............ 125
11.5.3 SWOT ANALYSIS ................ 125
11.5.4 financial analysis ................ 126
11.5.5 Key Strategy ....................... 126
11.6 LONZA GROUP AG ........................... 127
11.6.1 COMPANY OVERVIEW ......... 127
11.6.2 PRODUCT OFFERED ............ 128
11.6.3 Key Development ................ 128
11.6.4 SWOT ANALYSIS ................ 129
11.6.5 financial analysis ................ 130
11.6.6 Key Strategy ....................... 130
11.7 THERMO FISHER SCIENTIFIC (PATHEON) .......................................... 131
11.7.1 COMPANY OVERVIEW ......... 131
11.7.2 PRODUCT OFFERED ............ 132
11.7.3 Key Development ................ 132
11.7.4 SWOT ANALYSIS ................ 133
11.7.5 financial analysis ................ 134
11.7.6 Key Strategy ....................... 134
11.8 CAMBREX CORPORATION ........... 135
11.8.1 COMPANY OVERVIEW ......... 135
11.8.2 PRODUCT OFFERED ............ 136
11.8.3 Key Development ................ 136
11.8.4 SWOT ANALYSIS ................ 137
11.8.5 Key Strategy ....................... 137
11.9 CATALENT, INC. .............................. 138
11.9.1 COMPANY OVERVIEW ......... 138
11.9.2 PRODUCT OFFERED ............ 139
11.9.3 Key Development ................ 139
11.9.4 SWOT ANALYSIS ................ 140
11.9.5 financial analysis ................ 141
11.9.6 Key Strategy ....................... 141
11.10 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD ............................ 142
11.10.1 COMPANY OVERVIEW ......... 142
11.10.2 PRODUCT OFFERED ............ 143
11.10.3 Key Development ................ 143
11.10.4 SWOT ANALYSIS ................ 144
11.10.5 financial analysis ................ 145
11.10.6 Key Strategy ....................... 145